Publication at First Faculty of Medicine |
2012
Abstract
The addition of ezetimib in a dose of 10 mg in hyprlipidaemia patients who had not achieved the recommended target values of LDL-C resulted in a subsequent significant decrease of both TC and LDL-C. It also enabled to increase the number of patients achieving the recommended target plasma lipid values.
The treatment was safe and was not associated with adverse effects.